Common name
acetamide
IUPAC name
acetamide
SMILES
NC(=O)C
Common name
acetamide
IUPAC name
acetamide
SMILES
NC(=O)C
INCHI
InChI=1S/C2H5NO/c1-2(3)4/h1H3,(H2,3,4)
FORMULA
C2H5NO
Common name
acetamide
IUPAC name
acetamide
Molecular weight
59.067
clogP
-0.723
clogS
0.321
Frequency
0.0460
HBond Acceptor
1
HBond Donor
2
Total PolarSurface Area
43.09
Number of Rings
0
Rotatable Bond
0
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00769 | Repaglinide |
|
Hypoglycemic Agents; Antidiabetic Agents; Meglitinides; Drugs Used in Diabetes; Alimentary Tract and Metabolism; Blood Glucose Lowering Drugs, Excl. Insulins; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inducers; CYP3A4 Inhibitors; | As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. |
| FDBD00780 | Ceforanide |
|
Anti-Bacterial Agents; Cephalosporins; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Second-Generation Cephalosporins; | For the treatment of infections caused by susceptible organisms. |
| FDBD00803 | Mezlocillin |
|
Anti-Bacterial Agents; Penicillins; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials, Penicillins; Penicillins With Extended Spectrum; | Used to treat serious gram–negative infections of the lungs, urinary tract, and skin. |
| FDBD00817 | Zaleplon |
|
Hypnotics and Sedatives; Nervous System; Psycholeptics; Benzodiazepine Related Drugs; CYP3A4 Inhibitors; | For the treatment of short-term treatment of insomnia in adults. |
| FDBD00904 | Benzylpenicillin |
|
Anti-Bacterial Agents; Penicillins; Antibiotics; Ophthalmologicals; Sensory Organs; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Antiinfectives; Antibacterials for Intramammary Use; Beta-Lactam Antibacterials, Penicillins; Beta-Lactam Antibacterials, Penicillins, for Intramammary Use; Beta-Lactamase Sensitive Penicillins; | For use in the treatment of severe infections caused by penicillin G-susceptible microorganisms when rapid and high penicillin levels are required such as in the treatment of septicemia, meningitis, pericarditis, endocarditis and severe pneumonia. |
| FDBD00912 | Azlocillin |
|
Anti-Bacterial Agents; Penicillins; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Beta-Lactam Antibacterials, Penicillins; Penicillins With Extended Spectrum; | For the treatment of infections caused by . |
| FDBD00916 | Melatonin |
|
Antioxidants; Hypnotics and Sedatives; Central Nervous System Depressants; Nervous System; Psycholeptics; Melatonin Receptor Agonists; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; | Used orally for jet lag, insomnia, shift-work disorder, circadian rhythm disorders in the blind (evidence for efficacy), and benzodiazepine and nicotine withdrawal. Evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults. It has received FDA orphan drug status as an oral medication for this use. A number of studies have shown that melatonin may be effective for treating sleep-wake cycle disturbances in children and adolescents with mental retardation, autism, and other central nervous system disorders. It appears to decrease the time to fall asleep in children with developmental disabilities, such as cerebral palsy, autism, and mental retardation. It may also improve secondary insomnia associated with various sleep-wake cycle disturbances. Other possible uses for which there is some evidence for include: benzodiazepine withdrawal, cluster headache, delayed sleep phase syndrome (DSPS), primary insomnia, jet lag, nicotine withdrawal, preoperative anxiety and sedation, prostate cancer, solid tumors (when combined with IL-2 therapy in certain cancers), sunburn prevention (topical use), tardive dyskinesia, thrombocytopenia associated with cancer, chemotherapy and other disorders. |
| FDBD00923 | Atazanavir |
|
Anti-HIV Agents; Protease Inhibitors; HIV Protease Inhibitors; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; CYP3A4 Inhibitors; Combined Inhibitors of CYP3A4 and P-glycoprotein; | Used in combination with other antiretroviral agents for the treatment of HIV-1 infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission. |
| FDBD00987 | Cefapirin |
|
Anti-Bacterial Agents; Cephalosporins; Genito Urinary System and Sex Hormones; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; Antibacterials for Intramammary Use; Antiinfectives and Antiseptics for Intrauterine Use; First-Generation Cephalosporins; Antibacterials; | For treatment of infections caused by susceptible bacteria. |
| FDBD00989 | Micafungin |
|
Antifungal Agents; Antiinfectives for Systemic Use; Antimycotics for Systemic Use; | For use in the treatment of candidemia, acute disseminated candidiasis, and certain other invasive . |
134 ,
14
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 1wdn_ligand_1_2.mol2 | 1wdn | 1 | -5.99 | CC(=O)N | 4 |
| 4g4p_ligand_1_2.mol2 | 4g4p | 1 | -5.96 | C(=O)(N)C | 4 |
| 4kqp_ligand_1_2.mol2 | 4kqp | 1 | -5.96 | CC(=O)N | 4 |
| 1jak_ligand_frag_2.mol2 | 1jak | 1 | -5.94 | C(=O)(N)C | 4 |
| 2ntf_ligand_1_9.mol2 | 2ntf | 1 | -5.91 | C(=O)(N)C | 4 |
| 2jiw_ligand_frag_2.mol2 | 2jiw | 1 | -5.89 | NC(=O)C | 4 |
2564 ,
257
